



Original Scientific Article

THERAPEUTIC POTENTIAL OF *ASPARAGUS RACEMOSUS* AND *VITEX NEGUNDO* AGAINST POLYCYSTIC OVARIAN SYNDROME IN WISTAR RATS: EXPLORING AN OXIDATIVE STRESS INDEPENDENT MECHANISM

Angshita Ghosh, Tarun Kumar Kar, Sananda Sil, Ananya Barman,
Sandip Chattopadhyay

Department of Biomedical Laboratory Science and Management and Clinical Nutrition
and Dietetics, Vidyasagar University, Midnapore-721102, West Bengal, India

Received 9 July 2024; Received in revised form 18 January 2025; Accepted 25 April 2025

ABSTRACT

Polycystic ovarian syndrome (PCOS) is the most predominant endocrine disorder responsible for female infertility. The clinical treatment strategies of PCOS only provide symptomatic relief but are often unsatisfactory. *Asparagus racemosus* and *Vitex negundo* have long been used as traditional herbal intervention in treating various metabolic and reproductive issues. Therefore, a pressing need for a better alternative approach is essential. The study aimed to assess the effect of *A. racemosus* (ARA) and *V. negundo* (VNA) aqueous extract on treating PCOS-like symptoms in female rats. Letrozole (1.0 mg/kg BW) was used to induce PCOS in rats which were then treated with ARA and VNA in a dose of 250 mg/kg BW orally for 21 consecutive days. These herbs improved the estrous cycle after being perturbed by letrozole. ARA and VNA significantly increased the level of estradiol and estradiol receptor (*ESR1*) in PCOS rats, which further prevented uterine shrinkage. Post treatment of these herbs also revealed a notable decline in serum glucose and triglyceride levels in letrozole-induced PCOS rats. Letrozole caused reproductive and metabolic alterations without inducing oxidative stress, evidenced by higher activity of SOD and catalase in PCOS group. However, both supplemented groups showed baseline level of SOD and catalase similar to the vehicle-treated control. Moreover, ARA and VNA administration decreased the appearance of cystic follicles in histomorphological study by regulating ovarian folliculogenesis. Hence, this is the first time we reported that restoration of normal reproductive and metabolic function in letrozole induced PCOS by ARA and VNA were independent of oxidative stress.

Key words: PCOS, Wistar rats, *Asparagus racemosus*, *Vitex negundo*, oxidative stress

INTRODUCTION

Polycystic ovarian syndrome (PCOS) is a complicated self-perpetuating endocrinopathy with worldwide occurrence ranging from 5-20% among females of reproductive age (1). PCOS encompasses the complex interplay of neuroendocrine, reproductive and metabolic disorders driven by a variety of environmental

and hereditary variables (2). Hyperandrogenism, menstrual irregularity and polycystic ovarian morphology are most persistent characteristics of PCOS, which eventually leads to anovulatory infertility (3). Prolonged hyperandrogenism causes alteration in gonadotropin secretion, disruption of the hypothalamic-pituitary-gonadal axis, abrupt luteinization of granulosa cells and aberration of ovarian steroidogenesis (4). Atypical expression of androgen-producing steroidogenic enzyme 3 β HSD is associated with consistent development of cystic follicles (5). Furthermore, improper functioning of the major female sex hormone estradiol via estradiol receptors (*ER α* and *ER β*) also contribute to PCOS by affecting egg maturation and ovulation (6). In addition, excess androgen also disrupts metabolic homeostasis by developing central adiposity, dyslipidemia, and hyperglycemia with

Corresponding author: Dr. Sandip Chattopadhyay, PhD

E-mail address: sandipdoc@yahoo.com

Present address: Department of Biomedical Laboratory Science and Management and Clinical Nutrition and Dietetics, Vidyasagar University, Midnapore-721102, West Bengal, India

Phone: +917501568191

Copyright: © 2025 Ghosh A. This is an open-access article published under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing Interests: The authors have declared that no competing interests exist.

Available Online First: 4 August 2025

Published on: 15 October 2025

<https://doi.org/10.2478/macvetrev-2025-0026>

decreased insulin sensitivity (3). Hyperglycemic condition stimulates ROS generation from the leukocytes by eliciting a pro-oxidative response in PCOS (7). The etiology of PCOS in the context of oxidative stress may entail cellular organelle dysfunction as documented from the report of metabolic and molecular alterations (8). Nevertheless, it is undefined if oxidative stress contributes directly in the establishment of PCOS or if it only develops as a secondary ailment due to hyperglycemia and insulin resistance.

Altogether, the complex combination of all these factors makes PCOS a challenging condition for executing proper diagnosis and treatment. Modern therapeutic strategies frequently involve a combined medication therapy including anti-androgenic drugs, metformin and oral contraceptive pills for the treatment of PCOS. Metformin is effective to treat metabolic disturbances in obese PCOS women by normalizing the glycemic homeostasis (9). Antiandrogenic drugs are often used in treatment of clinical hyperandrogenism such as hirsutism in PCOS (10). Combined oral contraceptives are mainly used in the improvement of menstrual irregularities and provide protection to endometrium in PCOS (11). The presently available medical interventions, have merely alleviating effects and usually have severe side effects (12). This has boosted the interest in traditional effective herbal remedies which are safer and non-invasive in the treatment of PCOS. Ayurvedic therapies for PCOS strive to maintain optimal *dosha* (energies) balance, notably *Vata* (biological air or movement energy) and *Kapha* (biological water or mucus), through dietary adjustments, herbal medications, lifestyle changes, and stress management (13). Implementing herbal remedies in the regular diet has become a new trend for managing PCOS (14). Shatavari (*Asparagus racemosus*) and nirgundi (*Vitex negundo*) are famous traditional Ayurvedic herbs with broad range of therapeutic advantages (15, 16). Ayurveda describes Shatavari as ‘the Queen of herbs’ with revitalizing properties that limits women’s reproductive health disorders by soothing *Vata* and *Pitta* (metabolic energy) doshas (15, 17). On the other hand, *Vitex negundo* is well known as Nirgundu, Punjgusht, Sephali, or Sambhalu with a balancing impact on *Vata* and *kapha* doshas (18, 19). The roots of *A. racemosus* is a multifunctional hormone-balancing feminine tonic that promotes fertility by nourishing reproductive organs. Previous clinical study also suggested ayurvedic formulation including shatavari and other herbs which were successfully

used for treatment of subfertility in PCOS women (20). However, the seeds of *V. negundo* counteracts hyperandrogenism and thereby maintains the normal follicular advancement, minimizing PCOS symptoms (21). Several studies have pointed out that both herbs possess antioxidant, hypolipidemic, immunomodulatory, and anti-inflammatory properties without producing undesired side effects (16, 22). Although, *A. racemosus* and *V. negundo* have been extensively studied for their medicinal properties, there are scarce evidence on their effect in the treatment of PCOS. Hence, this study aimed to assess the therapeutic effect of *A. racemosus* (roots) and *V. negundo* (seeds) on estrous cycle patterns, estradiol level and its receptors expression, steroidogenesis, folliculogenesis, metabolic parameters, and oxidative/antioxidative status in Wistar rats with PCOS. Additionally, the study focused to elucidate the pathophysiological mechanisms of PCOS through assessment of these effects.

MATERIAL AND METHODS

Chemicals

Letrozole tablets were obtained from Sun Pharmaceutical Ltd, Bengaluru, India. All the consumables were provided from Hi Media (India), and Merck (India).

Aqueous extraction of *A. racemosus* roots and *V. negundo* seeds

Roots of *A. racemosus* and seeds of *Vitex negundo* were collected from the local Ayurvedic Pharmaceutical Shop (Midnapore, West Bengal) and grounded into powder form. Each set of powdered herbs of 100 g was dissolved into 1000 mL of distilled water and continuously stirred for 2 days before filtration. The filtrates were then concentrated in a rotary evaporator. Collected concentrates were air-dried and stored for the experiment. The total yield of the aqueous extracts of *A. racemosus* and *V. negundo* were 17.23 g and 13.73 g, respectively. Roots and seeds of *A. racemosus* and *V. negundo* were used according previous reports (21, 23).

Selection of specific dosages

A. racemosus and *V. negundo* were administered at a dose of 250 mg/kg BW according to the findings of a previous *in vitro* screening (data not shown) and published reports (21, 23).

Animal selection and care

Female albino rats (n=24), with 100-120 g body weight and 6-8 weeks old, were acclimatized for 8 days at 25 °C and 50-70% humidity. The animals were procured from an authorized animal provider (M/S Chakraborty Enterprise; Regd no. 1443/PO/Bt/s/11/CPCSEA; India). All the rats were kept in polycarbonate cages with adequate access to food and water ad libitum.

Ethical approval

The Animal Ethics Committee of Vidyasagar University approved the experiment with ethical clearance number VU/IAEC/CPCSEA/19/7/2022 dt.22.11.2022 (*A. racemosus*) and VU/IAEC/CPCSEA/17/7/2022 dt.22.11.2022 (*V. negundo*). The experiment was carried out in compliance with the norms specified by the CPCSEA (Committee for the Purpose of Control and Supervision of Experiments on Animals), India. This study also followed the EU Directive guidelines (2010/63/EU) for the protection and care of laboratory animals and experimental protocols used for scientific purposes.

PCOS induction and experimental design

Letrozole (1.0 mg/kg BW) was diluted in 0.5% carboxymethyl cellulose (CMC) and administered orally for 21 consecutive days to develop PCOS (20). Total twenty-four Wistar rats were divided into the following four groups:

1. Control Group: received 0.5% CMC orally for 21 days;
2. PCOS Group: letrozole (1.0 mg/kg BW) was suspended in 0.5% CMC and administered orally to rats for the first 21 days (24, 25);
3. ARA Group: oral administration of letrozole (1.0 mg/kg BW) for 1st 21 days + post administration of ARA (*A. racemosus* roots aqueous extract; 250 mg/kg) via oral route for the next 21 days (23);
4. VNA Group: oral administration of letrozole (1mg/kg BW) for 1st 21 days + post administration of VNA (*V. negundo* seeds aqueous extract; 250 mg/kg) orally for the next 21 days (21).

The experiment was conducted for 42 days. Rats were closely monitored regularly for changes in body weight, estrous cycle, and other discomfort signs. On day 43, all rats were sacrificed using anesthetic Ketamine/HCl (80 mg/kg BW, intraperitoneal injection) and xylazine (8 mg/kg BW, intraperitoneal

injection) following the guidelines of CPCSEA, India. Serum and organs were procured and stored at -20 °C for further analysis.

Vaginal smear observation

Vaginal cytology studies were performed on regular basis throughout the whole investigation. A sterile dropper filled with 100 µL of normal saline was carefully inserted into the vaginal region of the rat for the collection of vaginal fluid. Collected vaginal fluid was transferred on glass slides and was air-dried. Slides were then stained with Leishman stain and observed under a light microscope.

Body weight and organs weight measurement

The body weight of all animals was monitored regularly throughout the animal treatment. The final weight was recorded according to the standard protocol. Reproductive organs weight was also measured after sacrificing.

Serum analysis

The serum was collected from the blood following centrifugation at 2,500 rpm for 6 min. Serum glucose, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels in serum were measured using kit assay procedures according to manufacturer specifications.

ELISA of estradiol, estradiol receptor (ESR1), and steroidogenic enzyme 3-beta hydroxysteroid dehydrogenase (3βHSD)

ELISA kits were used to assess serum estradiol, ESR1, and 3βHSD (ovarian tissue specific) in compliance with the manufacturer's recommendations. The reading was taken spectrophotometrically at 450 nm.

Spectrophotometric studies of superoxide dismutase (SOD) and catalase

Ovarian tissue (50 mg/mL) was homogenized in ice-cold lysis buffer (pH 8.4) and then centrifuged at 10,000 g for 15 min at 4 °C. The recovered supernatant (50 µL) was mixed with 10 mM pyrogallol and 50 mM Tris-HCl (pH 8.4), and wavelength was set at 420 nm to measure the absorbance change for SOD. The catalase was measured with the remaining part of the supernatant which was mixed with H₂O₂ solution. The change in absorbance was noted at 240 nm.

Native gel expression of SOD and catalase

The expression study of SOD and catalase was performed by using 12% and 8% native gels, respectively. Ovarian tissue (50 mg) was homogenized with chilled phosphate buffer solution (PBS; 1.0 mol/L, pH 7.4) and centrifuged at 10,000 g for 15 min at 4 °C. The tissue protein extract (50 µg) was further applied on 12% and 8% native PAGE.

Following electrophoresis, the 12% gel was incubated for 20 min in dark with 28 mM TEMED (tetramethylethylenediamine), 2.3 mM NBT (nitroblue tetrazolium), and 28 mM riboflavin to observe SOD expression (26).

Similarly, the 8% gel was incubated in 0.003% H₂O₂ solution before being exposed to 2% potassium ferricyanide and 2% ferric chloride solutions to generate achromatic catalase band (26).

Densitometry of the above achromatic band of electrozymogram was determined by the Image J software 1.54, National Institutes of Health, USA.

Histological study

The ovaries were promptly obtained and stored in formalin upon sacrifice. The tissue was then

fixed with paraformaldehyde and dehydrated with increasing concentration of ethanol. Following washing with xylene, ovarian tissues were fixed in paraffin and were serially sectioned with 5 µm thickness. Staining was performed with hematoxylin and eosin. The slides were viewed under light microscope.

Statistical analysis

ANOVA followed by the post hoc Tukey's test was performed using SPSS 16.0 software for the determination of statistical significance between the groups.

RESULTS

Effect on estrous cycle pattern

Letrozole-induced PCOS group showed alteration in estrous cycle followed by continuous diestrus phase. The vehicle-treated control group had typical estrous patterns. ARA and VNA groups showed longer estrus phase and decreased duration of the diestrus phase compared with the PCOS group (Fig. 1A and 1B).




Figure 1. Effects of ARA and VNA on the estrous cycle pattern (proestrus, estrus, metestrus and diestrus) of letrozole treated rats (N=6) (1A). Microscopic images of different phases of the estrus cycle at 10X magnification. Numerous nucleated cells (indicated by N) are present at the proestrus phase. Cornified epithelial cells are observed during the estrus phase (indicated by C). Few leukocytes (indicated by L) and cornified epithelial cells (C) with few nucleated cells (N) are present during the metestrus phase. At diestrus phase, mostly leukocytes (L) are observed. Control=Control group; PCOS=Polycystic ovary syndrome model group; ARA=*Asparagus racemosus* aqueous extract group; VNA=*Vitex negundo* aqueous extract group (1B)

Effect on body weight and organosomatic indices

A significantly higher body weight was observed in PCOS rats compared to the control group (Table 1). ARA and VNA supplementation had significantly lower body weight in PCOS-induced rats (Table 1).

No significant change in the ovarian weight was observed compared to the control. Uterine weight was significantly lower in PCOS rats compared to the control. Supplementation with ARA and VNA significantly (Table 1, Fig. 2) attenuated the uterine weight of PCOS rats.

Table 1. Effect of *A. racemosus* and *V. negundo* on body weight and organo-somatic indices in letrozole-induced PCOS group

Groups	Body weight (gm)		Organo-somatic indices (gm%)	
	Initial body weight	Final body weight	Ovary in pair	Uterus
CON	110.33±0.98 ^a	135.50±2.69 ^a	0.048±0.008 ^a	0.405±0.030 ^a
PCOS	110.50±0.76 ^a	150.16±2.28 ^b	0.043±0.002 ^a	0.171±0.020 ^b
ARA	111.16±1.07 ^a	141.00±1.29 ^{ac}	0.031±0.003 ^a	0.318±0.020 ^{ac}
VNA	112.50±1.60 ^a	146.83±1.22 ^{bc}	0.035±0.004 ^a	0.277±0.010 ^{cd}

Data are presented as mean±SE (N=6). Groups with different superscripts (^{a, b, c, d}) in a column indicate statistically significant differences at $p<0.05$. Statistical analysis was performed with ANOVA followed by Post hoc Tukey's test. CON=Control group; PCOS=Polycystic ovary syndrome model group; ARA=*Asparagus racemosus* aqueous extract group; VNA=*Vitex negundo* aqueous extract group




Figure 2. Morphological changes of ovaries and uterus. Very thin uterus was prominent in PCOS group compared to control. ARA and VNA group showed comparatively better uterine morphology in contrast to PCOS group. Control=Control group; PCOS=Polycystic ovary syndrome model group; ARA=*Asparagus racemosus* aqueous extract group; VNA=*Vitex negundo* aqueous extract group

Serum glucose and lipid profile

Significantly higher levels of blood glucose and dyslipidemia were observed in PCOS group than that of the control group. A significantly

lower serum glucose, LDL, and triglyceride were observed in the ARA and VNA post-treated groups (Table 2).

Table 2. Effect of *A. racemosus* and *V. negundo* on serum glucose and lipid profile in letrozole-induced PCOS group

Groups	GLUCOSE	LDL	HDL	TG
CON	128.35±3.53 ^a	25.61±1.44 ^a	20.61±1.08 ^a	56.75±1.71 ^a
PCOS	201.01±7.56 ^b	43.56±2.02 ^b	9.69±1.30 ^b	80.76±2.90 ^b
ARA	171.60±6.96 ^c	30.19±3.34 ^{ac}	13.49±1.91 ^{ab}	65.72±2.56 ^{ac}
VNA	173.00±6.40 ^{cd}	31.77±3.88 ^{acd}	12.405±2.67 ^{bc}	61.70±2.62 ^{acd}

Data are present as mean±SE (N=6). Groups with different superscripts (^{a, b, c, d}) in a column indicate statistically significant differences at $p < 0.05$. Statistical analysis was performed with ANOVA followed by Post hoc Tukey's test. CON=Control group; PCOS=Polycystic ovary syndrome model group; ARA=*Asparagus racemosus* aqueous extract group; VNA=*Vitex negundo* aqueous extract group

Effect on estradiol, *ESR1*, and 3β HSD

A significant suppression of estradiol level and weak signaling of *ESR1* were observed in the PCOS group compared to the control. Decreased concentration of the steroidogenic enzyme

3β HSD was also observed in the PCOS group. Post-treatment of ARA and VNA significantly upregulated the action of estradiol and *ESR1*, whereas a non-significant increase in 3β HSD was noted following treatment (Fig. 3).




Figure 3. Concentration of serum estradiol (ng/mL), *ESR1* (ng/mL), and steroidogenic enzymes 3β HSD (ng/mL) in ovarian tissue. Each bar represents mean±SE (N=6). Groups with different superscripts (^{a, b, c, d}) indicate statistically significant differences at $p < 0.05$. Statistical analysis was performed with ANOVA followed by Post hoc Tukey's test. CON=Control group; PCOS=Polycystic ovary syndrome model group; ARA=*Asparagus racemosus* aqueous extract group; VNA=*Vitex negundo* aqueous extract group

Antioxidant status

Pyrogallol autoxidation and H_2O_2 test revealed significantly higher activity of SOD and catalase in PCOS compared to the other groups (Fig. 4A). The ARA and VNA groups had non-significantly different antioxidant enzyme activity compared to

the control (Fig. 4A). Native gel expression showed higher band density of these antioxidant enzymes in the PCOS group and lower density in ARA and VNA groups (Fig. 4B).




Figure 4. Activity of SOD (Unit/mg of protein) and CAT (Unit/mg of protein) in the ovarian tissue. Each bar represents mean $\pm$ SE (N=6). Groups with different superscripts (^a, ^b, ^c, ^d) indicate statistically significant differences at $p < 0.05$. Statistical analysis was performed with ANOVA followed by Post hoc Tukey's test (**4A**). Electrozymographic evaluation of the expression pattern of ovarian antioxidant enzymes SOD and catalase on 12% and 8.0% native gel electrophoresis. Image J software was used for the determination of densitometric percentage (%) of each band. CON=Control group; PCOS=Polycystic ovary syndrome model group; ARA=*Asparagus racemosus* aqueous extract group; VNA=*Vitex negundo* aqueous extract group (**4B**)

Histological analysis of ovary

Light-microscopic images (10x and 40x) of ovary sections of the letrozole treated group (Fig. 5, Table 3) displayed multiple cystic follicles characterized with diminished granulosa cell layer

and enhanced follicular antrum. The ARA and VNA groups had lower number of observable cystic follicles compared with PCOS rats (Fig. 5, Table 3).

Table 3. Follicular count in ovaries

Groups	Primary follicles	Secondary follicles	Tertiary follicles	Corpus luteum	Cystic follicles
CON	20.33 $\pm$ 0.53 ^a	12.16 $\pm$ 0.24 ^a	6.33 $\pm$ 0.20 ^a	10.83 $\pm$ 0.64 ^a	0
PCOS	7.16 $\pm$ 0.24 ^b	1.16 $\pm$ 0.19 ^b	0.83 $\pm$ 0.12 ^b	1.50 $\pm$ 0.17 ^b	6.83 $\pm$ 0.24 ^b
ARA	13.50 $\pm$ 0.37 ^c	3.83 $\pm$ 0.12 ^c	2.33 $\pm$ 0.08 ^c	4.50 $\pm$ 0.17 ^c	3.33 $\pm$ 0.13 ^c
VNA	15.33 $\pm$ 0.40 ^{cd}	4.66 $\pm$ 0.17 ^{cd}	1.83 $\pm$ 0.12 ^{bc}	5.83 $\pm$ 0.19 ^{cd}	2.83 $\pm$ 0.12 ^{cd}

Data is presented as mean $\pm$ SE (N=6). Groups with different superscripts (^a, ^b, ^c, ^d) in a column indicate statistically significant differences at $p < 0.05$. Statistical analysis was performed with ANOVA followed by Post hoc Tukey's test. CON=Control group; PCOS=Polycystic ovary syndrome model group; ARA=*Asparagus racemosus* aqueous extract group; VNA=*Vitex negundo* aqueous extract group




Figure 5. Histological changes in ovarian tissue (10X and 40X) after 4-week treatment with *A. racemosus* and *V. negundo* on folliculogenesis and growth in letrozole-induced PCOS rats. PCOS group displayed multiple cystic follicles along with the thinning granulosa cell layer (B, B1) in comparison with control group (A, A1). Letrozole induced development of cystic follicle was corrected by the supplementation of *A. racemosus* (C, C1) and *V. negundo* (D, D1) by encouraging follicular growth and ovulation. Different follicular stages were indicated as follows: PF=primordial follicle; SF=secondary follicle; GF=Graafian follicle; DF=developing follicle; CL=corpus luteum; CF=cystic follicle; O=oocyte. Control=Control group; PCOS=Polycystic ovary syndrome model group; ARA=*Asparagus racemosus* aqueous extract group; VNA=*Vitex negundo* aqueous extract group

DISCUSSION

Letrozole is well documented to induce *in vivo* PCOS by interrupting the estrogen conversion from testosterone and causing excessive androgen accumulation in the ovaries, leading to endocrine imbalance (24). Hormonal alterations negatively perturbed the estrous cyclicity in the letrozole-treated rats. A continuous diestrus phase was observed in the PCOS group, as reflected by the predominant presence of leukocytes in the vaginal smear (Fig. 1). Administration of ARA and VNA for 21 days following the PCOS development tended towards a steadiness of normal estrous cyclicity by replacing the acyclic estrous pattern. This was confirmed from the exclusive presence of nucleated and non-nucleated cornified epithelium cells (Fig. 1).

Hyperandrogenism-mediated feedback signal to the pituitary gland leads to increased LH and decreased FSH output (27). Normally, diffusion of androgen to granulosa cells from theca cells acts as the substrate for estradiol formation in response to FSH (28). Alteration in LH:FSH ratio may further cause progression and persistence of sex steroid alteration. The present investigation observed

aberrant estradiol and *ESR1* activity in ovarian tissue, indicating improper estradiol signaling in letrozole-induced PCOS group (Fig. 3). Estradiol regulates ovarian follicular growth and maturation via *ESR1* and *ESR2* receptors (29). Additionally, this analysis found greater evidence of ovarian disturbances caused by uterine horn shrinkage (Fig. 2). A prior study confirmed the dose-dependent suppression of uterine weight in letrozole-induced PCOS (30). Dose-dependent uterine suppression may be due to reduced estradiol concentration, as circulating estradiol is critical for uterine growth (31). The phytoestrogenic actions of ARA and VNA significantly modified the endocrinal imbalance by enhancing circulatory estradiol and *ESR1* signaling (Fig. 3). In response to the structural and functional similarity with the mammalian 17β -estradiol, the binding of phytoestrogens to the estrogen receptors could exert an agonist or antagonistic effect on estrogen-responsive gene products (32). Administration of *A. racemosus* demonstrated estrogenic effect on genital organs and mammary glands in pregnant rats (33). At the same time, *V. negundo* has also been reported to enhance the estradiol level in letrozole-induced PCOS (21). Our results also confirmed the hormone modulatory

properties of *A. racemosus* and *V. negundo*, which in turn helps in modifying the estradiol and ER-mediated signaling in PCOS.

Production of the thecal steroidogenic enzymes is completely reliant on LH (34). Previous studies showed that cystic follicles express a higher amount of 3 β HSD compared to the normal follicles (35). The presence of higher 3 β HSD activity in ovarian granulosa cells of cystic follicles may provide additional precursors in the theca cells for the conversion of DHEA, which further leads to greater androgen production (35). Reduction in steroidogenic enzyme 3 β HSD in the letrozole-treated ovaries is another exceptional result observed in the present study (Fig. 3). Although, 3 β HSD is an important enzyme for androgen production, it is also essential for progesterone biosynthesis (36). A decrease in 3 β HSD may affect the synthesis of progesterone, resulting in a drop in FSH and an alteration in the LH:FSH ratio in the gonadal axis (31). Post-administration of ARA and VNA both exhibited minimal and non-significant enhancement in the concentration of ovarian 3 β HSD (Fig. 3), which signifies plausible uninterrupted progesterone biosynthesis.

In addition to the reproductive abnormalities, many women with PCOS also experience various metabolic issues like dyslipidemia, hyperglycemia, central adiposity, and insulin resistance, raising the risk of type 2 diabetes and cardiovascular disease (37). Hyperandrogenism is preferentially linked to intra-abdominal fat deposition and enhanced numbers of tiny subcutaneous abdominal adipocytes, which may limit subcutaneous adipose storage and thereby encourages metabolic dysfunction (38). The present investigation demonstrated that the letrozole-induced PCOS model exhibits several metabolic abnormalities, observed in PCOS women. Letrozole treated rats showed a significant increase in the body weight (Table 1). The letrozole group also displayed an enhancement of serum glucose along with the alteration of lipid profile (Table 2). Supplementation of *A. racemosus* successfully reduced the body weight significantly, whereas *V. negundo* showed non-significant effect. Both herbs exhibited potential hypoglycemic efficacy by controlling the blood glucose level against PCOS (Table 2). Enhanced levels of glycerol, cholesterol, and LDL have been noticed in the follicular fluids of PCOS patients, which affect the oocyte environment (39). ARA and VNA reversed this dyslipidemic condition by significantly reducing the triglycerides and LDL levels, but no significant alteration was detected for HDL (Table 2).

The intraovarian folliculogenesis process is also regulated by oxidative metabolism (8). Excessive ROS production affects meiosis II progression, abolishes gonadotropin secretion, DNA damage, and inhibits ATP production (8). PCOS has been linked with increased oxidative stress, which ultimately leads to intra-ovarian disturbance by impairing oocyte maturation and luteal progression (40). Earlier studies also established that letrozole-induced PCOS rats showed a suppression of antioxidant enzymes (41). Surprisingly, our present investigation noticed the increased activity of SOD and catalase in the letrozole-induced PCOS group (Fig. 4A and 4B). The increased activity of antioxidant enzymes reflected activation of intrinsic cellular defense mechanism to compensate the elevated oxidative stress in PCOS group. Since, letrozole was given for only the initial 21 days of the experiment, it was unable to preserve a significant level of oxidative stress during letrozole withdrawal for the next 21 days. The above instances may be due to the reversible mode of action where letrozole cessation immediately transits towards rapid recovery to adjust the normal homeostasis that results in reduced oxidative stress in the PCOS group. Despite the reduced oxidative stress, letrozole successfully developed polycystic ovaries as confirmed from the ovarian histoarchitecture (Fig. 5). Administration of ARA and VNA immediately after letrozole cessation showed a sharp reduction in antioxidant enzyme activity and its subsequent expression when compared to the PCOS group. However, the antioxidant activities (SOD and catalase) in both groups returned to baseline levels similar to vehicle-treated control group (Fig. 4A and 4B). From this specific angle, this result implied that the ARA and VNA effectively normalized the redox status without overstimulating the cellular antioxidant defense system. These observed findings indicated that the oxidative stress reduction might not be the primary therapeutic pathway involved in restoration of PCOS. Despite the contradiction in the status of antioxidative enzymes, *A. racemosus* and *V. negundo* have successfully corrected the reproductive as well as metabolic dysfunction in PCOS. These observed findings imply that the action of ARA and VNA may be target-specific involving hormonal regulation and improved metabolic homeostasis regardless of oxidative stress.

Histology of the letrozole-treated ovaries showed the presence of multiple cystic follicles with thinning of ovarian granulosa cells (Fig. 5).

ARA and VNA resulted in successful elimination of PCOS-associated symptoms, thickened granulosa cell layer, and maintenance of proper interaction between theca and granulosa cells (Fig. 5). Supplementation with *A. racemosus* promotes ovulation which was confirmed by the presence of graafian follicles, whereas *V. negundo* maintains follicular progression and maturation by dissolving the cystic follicles (Table 3, Fig. 5).

CONCLUSION

ARA and VNA successfully improved the metabolic and reproductive status in PCOS rats. It reduced cystic follicle occurrence and maintained usual folliculogenesis in an oxidative stress independent pathway. Additionally, the phytoestrogenic action of these herbs improved *ESR1* signaling by restoring the levels of estrogen and its receptors. This aided in synchronizing the estrous cycle during PCOS. However, more detailed investigations on hormonal signaling pathways and hypothalamic-pituitary-adrenal (HPA) axis are imperative for the appropriate explanation of the mechanism of action of these herbal drugs. Moreover, exploring multi dose dependent studies of these herbs in higher animal models and human trials is also necessary for providing further validation and development of therapeutic applications.

CONFLICT OF INTEREST

The authors declare that they have no financial or non-financial conflict of interest regarding authorship and publication of this article.

ACKNOWLEDGMENTS

We are grateful to the Swami Vivekananda Merit Cum Means Scholarship [WBP201646991226] for partially funding this research.

AUTHORS' CONTRIBUTION

AG participated in conceptualization, study design, methodology and wrote the original manuscript. TKK was involved in treatment protocol and histological analysis. SS was involved in extract preparation and

biochemical analysis. AB was involved in ELISA and native gel expression study. SC was involved in supervision and manuscript editing. All authors reviewed the results and approved the final version of this present manuscript.

REFERENCES

1. Escobar-Morreale, H.F. (2018). Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. *Nat Rev Endocrinol.* 14(5): 270-284.
<https://doi.org/10.1038/nrendo.2018.24>
PMid:29569621
2. Witchel, S.F., Oberfield, S.E., Peña, A.S. (2019). Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls [presentation]. *J Endocr Soc.* 3(8): 1545-1573.
<https://doi.org/10.1210/js.2019-00078>
PMid:31384717 PMCID:PMC6676075
3. Sanchez-Garrido, M.A., Tena-Sempere, M. (2020). Metabolic dysfunction in polycystic ovary syndrome: pathogenic role of androgen excess and potential therapeutic strategies. *Mol Metab.* 35, 100937.
<https://doi.org/10.1016/j.molmet.2020.01.001>
PMid:32244180 PMCID:PMC7115104
4. Palomba, S., Daolio, J., La Sala, G.B. (2017). Oocyte competence in women with polycystic ovary syndrome. *Trends Endocrinol Metab.* 28(3): 186-198.
<https://doi.org/10.1016/j.tem.2016.11.008>
PMid:27988256
5. Dadachanji, R., Shaikh, N., Mukherjee, S. (2018). Genetic variants associated with hyperandrogenemia in PCOS pathophysiology. *Genet Res Int.* 2018, 7624932.
<https://doi.org/10.1155/2018/7624932>
PMid:29670770 PMCID:PMC5835258
6. Xu, X.L., Deng, S.L., Lian, Z.X., Yu, K. (2021). Estrogen receptors in polycystic ovary syndrome. *Cells.* 10(2): 459.
<https://doi.org/10.3390/cells10020459>
PMid:33669960 PMCID:PMC7924872
7. González, F., Nair, K.S., Daniels, J.K., Basal, E., Schimke, J.M., Blair, H.E. (2012). Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women. *J Clin Endocrinol Metab.* 97(8): 2836-2843.
<https://doi.org/10.1210/jc.2012-1259>
PMid:22569241 PMCID:PMC3410256

8. Rudnicka, E., Duszewska, A.M., Kucharski, M., Tyczyński, P., Smolarczyk, R. (2022). Oxidative stress and reproductive function: oxidative stress in polycystic ovary syndrome. *Reproduction*. 164(6): F145-F154.
<https://doi.org/10.1530/REP-22-0152>
PMid:36279177
9. Jensterle, M., Kravos, N.A., Ferjan, S., Goricar, K., Dolzan, V., Janez, A. (2020). Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort. *Endocr Connect*. 9(1): 44-54.
<https://doi.org/10.1530/EC-19-0449>
PMid:31829964 PMCID:PMC6993269
10. Alesi, S., Forslund, M., Melin, J., Romualdi, D., Peña, A., Tay, C.T., Witchel, S.F., et al. (2023). Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. *EClinicalMedicine*. 63, 102162.
<https://doi.org/10.1016/j.eclinm.2023.102162>
PMid:37583655 PMCID:PMC10424142
11. Forslund, M., Melin, J., Alesi, S., Piltonen, T., Romualdi, D., Tay, C.T., Witchel, S., et al. (2023). Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis. *Eur J Endocrinol*. 189(1): S1-S16.
<https://doi.org/10.1093/ejendo/lvad082>
PMid:37440702
12. Lanzo, E., Monge, M., Trent, M. (2015). Diagnosis and management of polycystic ovary syndrome in adolescent girls. *Pediatr Ann*. 44(9): e223-230.
<https://doi.org/10.3928/00904481-20150910-10>
PMid:26431241 PMCID:PMC5659205
13. Rathee, P., Rathee, S. (2022). A review of polycystic ovarian syndrome in Ayurveda. *IRJAY* 05(2): 114-117.
<https://doi.org/10.47223/IRJAY.2022.5220>
14. Lakshmi, J.N., Babu, A.N., Kiran, S.S.M., Nori, L.P., Hassan, N., Ashames, A., Bhandare, R.R., Shaik, A.B. (2023). Herbs as a source for the treatment of polycystic ovarian syndrome: A systematic review. *BioTech (Basel)*. 12(1): 4.
<https://doi.org/10.3390/biotech12010004>
PMid:36648830 PMCID:PMC9844343
15. Alok, S., Jain, S.K., Verma, A., Kumar, M., Mahor, A., Sabharwal, M. (2013). Plant profile, phytochemistry and pharmacology of *Asparagus racemosus* (Shatavari): a review. *Asian Pac J Trop Dis*. 3(3): 242-251.
[https://doi.org/10.1016/S2222-1808\(13\)60049-3](https://doi.org/10.1016/S2222-1808(13)60049-3)
16. Tandon, V.R. (2005). Medicinal uses and biological activities of *Vitex negundo*. *Nat Prod Rad*. 4(3): 162-165.
17. Pandey, A.K., Gupta, A., Tiwari, M., Prasad, S., Pandey, A.N., Yadav, P.K., et al. (2018). Impact of stress on female reproductive health disorders: possible beneficial effects of shatavari (*Asparagus racemosus*). *Biomed Pharmacother*. 103, 46-49.
<https://doi.org/10.1016/j.biopha.2018.04.003>
PMid:29635127
18. Bano, U., Jabeen, A., Ahmed, A., Siddiqui, M.A. (2015). Therapeutic uses of *Vitex nigundo*. *World J Pharm Med*. 4(12): 589-606.
19. Jajra, S.D., Panwar, N., Adlakha, M.K., Purvia, R.P., Gautam, V., Singh, C. (2019). Role of (*Vitex negundo*) nirgundi in pain management. *World J Pharm Med*. 8(7): 2083-2089.
20. Siriwardene, S.D., Karunathilaka, L.A., Kodituwakku, N.D., Karunaratne, Y.A. (2010). Clinical efficacy of Ayurveda treatment regimen on Subfertility with polycystic ovarian syndrome (PCOS). *AYU* 31(1): 24-27.
<https://doi.org/10.4103/0974-8520.68203>
PMid:22131680 PMCID:PMC3215317
21. Kakadia, N., Patel, P., Deshpande, S., Shah, G. (2018). Effect of *Vitex negundo* L. seeds in letrozole induced polycystic ovarian syndrome. *J Tradit Complement Med*. 9(4): 336-345.
<https://doi.org/10.1016/j.jtcme.2018.03.001>
PMid:31453130 PMCID:PMC6701941
22. Singh, R. (2016). *Asparagus racemosus*: a review on its phytochemical and therapeutic potential. *Nat Prod Res*. 30(17): 1896-1908.
<https://doi.org/10.1080/14786419.2015.1092148>
PMid:26463825
23. Soren, A.D., Yadav, A.K. (2021). Studies on the anthelmintic potentials of the roots of *Asparagus racemosus* willd. *Clin Phytosci*. 7, 32.
<https://doi.org/10.1186/s40816-021-00270-8>
24. Kafali, H., Iriadam, M., Ozardalı, I., Demir, N. (2004). Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. *Arch Med Res*. 35(2): 103-108.
<https://doi.org/10.1016/j.arcmed.2003.10.005>
PMid:15010188
25. Balasubramanian, A., Pachappan, S., Mohan, S., Adhikesavan, H., Karuppasamy, I., Ramalingam, K. (2023). Therapeutic exploration of polyherbal formulation against letrozole induced PCOS rats: a mechanistic approach. *Heliyon*. 9(5): e15488.
<https://doi.org/10.1016/j.heliyon.2023.e15488>
PMid:37180914 PMCID:PMC10173408

26. Weydert, C.J., Cullen, J.J. (2010). Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. *Nat Protoc.* 5(1): 51-66.
<https://doi.org/10.1038/nprot.2009.197>
PMid:20057381 PMCID:PMC2830880
27. Rosenfield, R.L., Ehrmann, D.A. (2016). The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. *Endocr Rev.* 37(5): 467-520.
<https://doi.org/10.1210/er.2015-1104>
PMid:27459230 PMCID:PMC5045492
28. Gervásio, C.G., Bernuci, M.P., Silva-de-Sá, M.F., Rosa-e-Silva, A.C. (2014). The role of androgen hormones in early follicular development. *ISRN Obstet Gynecol.* 2014, 818010.
<https://doi.org/10.1155/2014/818010>
PMid:25006485 PMCID:PMC4003798
29. Chauvin, S., Cohen-Tannoudji, J., Guigon, C.J. (2022). Estradiol signaling at the heart of folliculogenesis: its potential deregulation in human ovarian pathologies. *Int J Mol Sci.* 23(1): 512.
<https://doi.org/10.3390/ijms23010512>
PMid:35008938 PMCID:PMC8745567
30. Bries, A.E., Webb, J.L., Vogel, B., Carrillo, C., Keating, A.F., Pritchard, S.K., Roslan, G., et al. (2021). Letrozole-induced polycystic ovary syndrome attenuates cystathionine- β synthase mRNA and protein abundance in the ovaries of female Sprague Dawley rats. *J Nutr.* 151(6): 1407-1415.
<https://doi.org/10.1093/jn/nxab038>
PMid:33758914 PMCID:PMC8169814
31. Mandalà, M. (2020). Influence of estrogens on uterine vascular adaptation in normal and preeclamptic pregnancies. *Int J Mol Sci.* 21(7): 2592.
<https://doi.org/10.3390/ijms21072592>
PMid:32276444 PMCID:PMC7177259
32. Kuiper, G.G., Lemmen, J.G., Carlsson, B.O., Corton, J.C., Safe, S.H., Van Der Saag, P.T., van der Burg, B., Gustafsson, J.A. (1998). Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β . *Endocrinology.* 139(10): 4252-4263.
<https://doi.org/10.1210/endo.139.10.6216>
PMid:9751507
33. Sabnis, P.B., Gaitonde, B.B., Jetmalani M. (1968). Effects of alcoholic extracts of *Asparagus racemosus* on mammary glands of rats. *Indian J Exp Biol.* 6(1): 55-57.
34. Payne, A.H., Hales, D.B. (2004). Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. *Endocr Rev.* 25(6): 947-970.
<https://doi.org/10.1210/er.2003-0030>
PMid:15583024
35. Sun, Y., Zhang, J., Ping, Z., Fan, L., Wang, C., Li, W., Lu, C., Zheng, L., Zhou, X. (2011). Expression of 3β -hydroxysteroid dehydrogenase (3β -HSD) in normal and cystic follicles in sows. *Afr J Biotechnol.* 10(32): 6184-6189.
36. Hu, J., Zhang, Z., Shen, W.J., Azhar, S. (2010). Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. *Nutr Metab (Lond).* 7, 47.
<https://doi.org/10.1186/1743-7075-7-47>
PMid:20515451 PMCID:PMC2890697
37. Bednarska, S., Siejka, A. (2017). The pathogenesis and treatment of polycystic ovary syndrome: what's new? *Adv Clin Exp Med.* 26(2): 359-367.
<https://doi.org/10.17219/acem/59380>
PMid:28791858
38. Dumesic, D.A., Akopians, A.L., Madrigal, V.K., Ramirez, E., Margolis, D.J., Sarma, M.K., Thomas, A.M., et al. (2016). Hyperandrogenism accompanies increased intra-abdominal fat storage in normal weight polycystic ovary syndrome women. *J Clin Endocrinol Metab.* 101(11): 4178-4188.
<https://doi.org/10.1210/jc.2016-2586>
PMid:27571186 PMCID:PMC5095243
39. Zhang, Y., Liu, L., Yin, T.L., Yang, J., Xiong, C.L. (2017). Follicular metabolic changes and effects on oocyte quality in polycystic ovary syndrome patients. *Oncotarget.* 8(46): 80472-80480.
<https://doi.org/10.18632/oncotarget.19058>
PMid:29113318 PMCID:PMC5655213
40. Zuo, T., Zhu, M., Xu, W. (2016). Roles of oxidative stress in polycystic ovary syndrome and cancers. *Oxid Med Cell Longev.* 2016, 8589318.
<https://doi.org/10.1155/2016/8589318>
PMid:26770659 PMCID:PMC4684888
41. Younas, A., Hussain, L., Shabbir, A., Asif, M., Hussain, M., Manzoor, F. (2022). Effects of *Fagonia indica* on letrozole-induced polycystic ovarian syndrome (PCOS) in young adult female rats. *Evid Based Complement Alternat Med.* 2022, 1397060.
<https://doi.org/10.1155/2022/1397060>
PMid:35664938 PMCID:PMC9162856

Please cite this article as: Ghosh A., Kar T.K., Sil S., Barman A., Chattopadhyay S. Therapeutic potential of *Asparagus racemosus* and *Vitex negundo* against Polycystic ovarian syndrome in Wistar rats: exploring an oxidative stress independent mechanism. *Mac Vet Rev* 2025; 48 (2): 217-228. <https://doi.org/10.2478/macvetrev-2025-0026>